Figure 2From: Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments Results of time-to-progression (TTP) by treatment schedule (Weekly vs. 3-Weekly). Number of patients still at risk for 3-weekly (1) and weekly (2) treatment schedule are reported above the X axis.Back to article page